These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
    Author: Bays HE, Maki KC, Doyle RT, Stein E.
    Journal: Postgrad Med; 2009 Sep; 121(5):145-50. PubMed ID: 19820283.
    Abstract:
    BACKGROUND: Prescription omega-3-acid ethyl ester (P-OM3; Lovaza) therapy is indicated for treating very high triglyceride levels (>or= 500 mg/dL) at a dose of 4 g/day. The caloric content associated with each 1-g capsule of P-OM3 is approximately 11 Cal (Cal = kilocalories) - approximately 9 Cal from the oil in the capsule that contains omega-3 fat and approximately 2 Cal attributed to the components of the capsule shell. Thus, the 4-g/day dose contributes approximately 44 Cal/day, with approximately 36 Cal/day derived from the oil. METHODS: This analysis evaluated 167 dyslipidemic (triglycerides: >or= 500 mg/dL and < 1300 mg/dL), overweight/obese (body mass index [BMI] >or= 25 kg/m(2) and <or= 43 kg/m(2)) patients aged 18 to 79 years. Data were derived from an 8-week, randomized, double-blinded, placebo-controlled, parallel-group trial comparing P-OM3 4 g/day + fenofibrate 130 mg/day (n = 84) versus placebo (4 g/day of corn oil) + fenofibrate 130 mg/day (n = 83), and an 8-week open-label extension (n = 117), during which all subjects received P-OM3 + fenofibrate. Subjects who received P-OM3 + fenofibrate continued the same treatment in the extension phase (non-switchers; n = 59). Those who initially received corn oil placebo + fenofibrate received P-OM3 + fenofibrate in the extension phase (switchers; n = 58). RESULTS: During the 8-week double-blind phase in subjects receiving fenofibrate, the addition of P-OM3 (versus placebo) did not significantly change median (minimum, maximum) body weight (P-OM3 = 0 [-4.6, +4.2] kg, placebo = 0 [-3.6, +5.5] kg; P = 0.088) or waist circumference (P-OM3 = +0.1 [-12.1, +17.5] cm, placebo = +0.5 [-9.9, +12.2] cm; P = 0.162). In the 8-week extension phase, non-switchers and switchers did not differ in median change from the end of the double-blind phase in body weight (non-switchers = +0.2 [-3.2, +5.6] kg, switchers = +0.1 [-6.9, +7.9] kg; P = 0.982), or waist circumference (non-switchers = +0.1 [-9.8, +41.8] cm, switchers = +0.2 [-12.0, +7.0] cm; P = 0.685). CONCLUSION: When coadministered with fenofibrate for up to 16 weeks, the modest daily caloric contribution of P-OM3 (4 g/day) did not alter body weight or waist circumference compared with baseline or compared with fenofibrate plus placebo in patients with very high triglyceride levels.
    [Abstract] [Full Text] [Related] [New Search]